Recent Research Analysts’ Ratings Changes for Boston Scientific (BSX)

A number of firms have modified their ratings and price targets on shares of Boston Scientific (NYSE: BSX) recently:

• 10/30/2026 – Boston Scientific had its price target lowered by Barclays from $48.00 to $45.00. They now have an “equal weight” rating on the stock.
• 10/30/2026 – Boston Scientific was downgraded by TD Cowen from “buy” to “hold”. They now have a $46.00 price target on the stock, down from $56.00.
• 10/29/2026 – Boston Scientific had its price target lowered by Royal Bank Of Canada from $70.00 to $52.00. They now have an “outperform” rating on the stock.
• 10/29/2026 – Boston Scientific was given a new $48.00 price target by Deutsche Bank Aktiengesellschaft. They now have a “buy” rating on the stock.
• 10/29/2026 – Boston Scientific had its price target lowered by Royal Bank Of Canada from $70.00 to $52.00. They now have an “outperform” rating on the stock.
• 10/29/2026 – Boston Scientific had its price target lowered by Citigroup from $48.00 to $44.00. They now have a “neutral” rating on the stock.
• 10/29/2026 – Boston Scientific had its price target lowered by Leerink Partners from $55.00 to $50.00. They now have an “outperform” rating on the stock.
• 10/29/2026 – Boston Scientific was given a new $50.00 price target by Mizuho.
• 10/29/2026 – Boston Scientific had its price target lowered by Canaccord Genuity Group from $66.00 to $48.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Boston Scientific had its price target lowered by Sanford C. Bernstein from $54.00 to $49.00. They now have an “outperform” rating on the stock.
• 10/29/2026 – Boston Scientific had its price target lowered by UBS Group from $67.00 to $57.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Boston Scientific had its price target lowered by Wells Fargo & Company from $48.00 to $45.00. They now have an “equal weight” rating on the stock.
• 10/29/2026 – Boston Scientific had its price target lowered by BTIG Research from $56.00 to $49.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Boston Scientific had its price target raised by Robert W. Baird from $50.00 to $51.00. They now have an “outperform” rating on the stock.
• 10/29/2026 – Boston Scientific was downgraded by Oppenheimer from “outperform” to “market perform”.
• 10/28/2026 – Boston Scientific was downgraded by Jefferies Financial Group from “buy” to “hold”. They now have a $46.00 price target on the stock, down from $60.00.
• 10/28/2026 – Boston Scientific was downgraded by JPMorgan Chase & Co. from “overweight” to “neutral”. They now have a $46.00 price target on the stock.
• 10/28/2026 – Boston Scientific had its price target lowered by Needham & Company LLC from $57.00 to $48.00. They now have a “buy” rating on the stock.
• 10/26/2026 – Boston Scientific had its price target lowered by Stifel Nicolaus from $60.00 to $55.00. They now have a “buy” rating on the stock.
• 10/20/2026 – Boston Scientific had its “buy” rating reaffirmed by TD Cowen. They now have a $56.00 price target on the stock, down from $61.00.
• 10/15/2026 – Boston Scientific had its price target lowered by Robert W. Baird from $53.00 to $50.00. They now have an “outperform” rating on the stock.
• 10/14/2026 – Boston Scientific had its price target lowered by Truist Financial from $57.00 to $51.00. They now have a “buy” rating on the stock.
• 10/13/2026 – Boston Scientific was given a new $55.00 price target by Mizuho.
• 10/9/2026 – Boston Scientific had its price target lowered by Leerink Partners from $60.00 to $55.00. They now have an “outperform” rating on the stock.
• 10/7/2026 – Boston Scientific had its price target lowered by Evercore from $65.00 to $52.00. They now have an “outperform” rating on the stock.
• 10/7/2026 – Boston Scientific was upgraded by Barclays to “hold”.
• 10/6/2026 – Boston Scientific is now covered by Barclays. They set an “equal weight” rating and a $48.00 price target on the stock.
• 10/5/2026 – Boston Scientific had its price target lowered by Citigroup from $50.00 to $48.00. They now have a “neutral” rating on the stock.
• 10/3/2026 – Boston Scientific had its “outperform” rating reaffirmed by Sanford C. Bernstein. They now have a $54.00 price target on the stock, down from $60.00.
• 10/2/2026 – Boston Scientific had its “sell (d+)” rating reaffirmed by Weiss Ratings.
• 9/23/2026 – Boston Scientific had its price target lowered by Wells Fargo & Company from $50.00 to $48.00. They now have an “equal weight” rating on the stock.
• 9/21/2026 – Boston Scientific had its price target lowered by Oppenheimer from $85.00 to $65.00. They now have an “outperform” rating on the stock.
• 9/17/2026 – Boston Scientific had its “buy” rating reaffirmed by TD Cowen.
• 9/17/2026 – Boston Scientific was downgraded by Citigroup from “buy” to “neutral”. They now have a $50.00 price target on the stock, down from $57.00.
• 9/9/2026 – Boston Scientific had its price target lowered by BTIG Research from $60.00 to $56.00. They now have a “buy” rating on the stock.

Boston Scientific Trading Up 5.1%

BSX traded up $2.23 on Wednesday, reaching $45.73. 34,550,987 shares of the company traded hands, compared to its average volume of 19,306,746. The company has a market cap of $66.29 billion, a P/E ratio of 19.38, a price-to-earnings-growth ratio of 1.27 and a beta of 0.60. The company has a quick ratio of 0.74, a current ratio of 1.36 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a one year low of $39.57 and a one year high of $105.65. The firm has a fifty day simple moving average of $44.47 and a two-hundred day simple moving average of $56.16.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, hitting analysts’ consensus estimates of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same period in the prior year, the firm earned $0.75 EPS. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. As a group, equities research analysts expect that Boston Scientific Corporation will post 3.17 earnings per share for the current year.

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.